SINO BIOPHARM(HK:01177) Di Yi Cai Jing·2025-04-22 07:33Group 1 - The Zhongsheng Leading Fund, initiated by Pudong Venture Capital and China National Pharmaceutical Group, aims for a total scale of 1 billion yuan, with an initial closing scale of 500 million yuan [1] - The fund focuses on investing in growth-stage innovative biopharmaceutical companies, supporting them throughout the entire process of research, production, and sales [1] - Pudong New Area plans to continuously build platforms, integrate resources, optimize services, and gather talent to support the high-quality development of the biopharmaceutical industry [1] Group 2 - The biopharmaceutical industry is a core driver of new productive forces in Pudong New Area, which has become one of the most complete and innovative regions for biopharmaceutical industry chains in China [2] - The biopharmaceutical industry scale in Pudong is projected to reach 410 billion yuan by 2024 [2] Group 3 - The biopharmaceutical sector is currently facing a capital winter, with a 9.3% year-on-year decline in medical financing scale expected in 2024 [3] - There is a pressing need for state-owned enterprises to establish biopharmaceutical industry funds to address financing difficulties, long cycles, and high risks in the industry [3] - The Zhongsheng Leading Fund aims to create an innovative model of "state-owned guidance + industry leader empowerment" to align with the development plans of Shanghai and Pudong's biopharmaceutical industry [3]